Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 20/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 18/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 11/20 | 0.50 |
| ▸ | TMIGD3 | P0DMS9 | 2/20 | 0.46 |
| ▸ | HTR2C | P28335 | 2/20 | 0.46 |
| ▸ | HTR2B | P41595 | 2/20 | 0.46 |
| ▸ | HTR3A | P46098 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29575031 | 0.90 | ADORA3 (0.46) | ADORA3ADORA1ADORA2ATMIGD3HTR2C | |
| SCHEMBL29573771 | 0.87 | ADORA3 (0.61) | ADORA3ADORA1ADORA2ATMIGD3HTR2C | |
| SCHEMBL29573310 | 0.86 | ADORA3 (0.54) | ADORA3ADORA1ADORA2ATMIGD3HTR2C | |
| SCHEMBL29574441 | 0.85 | ADORA3 (0.41) | ADORA3ADORA1ADORA2A | |
| SCHEMBL29573875 | 0.84 | HRH2 (0.53) | ADORA3ADORA1ADORA2ATMIGD3HTR2C | |
| SCHEMBL29573460 | 0.84 | ADORA3 (0.39) | ADORA3ADORA1ADORA2ATMIGD3HTR2C | |
| SCHEMBL29573618 | 0.84 | ADORA3 (0.39) | ADORA3ADORA1ADORA2ATMIGD3HTR2C | |
| SCHEMBL29573594 | 0.84 | ADORA3 (0.44) | ADORA3ADORA1ADORA2A | |
| SCHEMBL29573299 | 0.82 | ADORA3 (0.50) | ADORA3ADORA1ADORA2ATMIGD3HTR2C | |
| SCHEMBL29573308 | 0.82 | ADORA3 (0.78) | ADORA3ADORA1ADORA2ATMIGD3HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4196219-A1 | A3 ADENOSINE RECEPTOR AGONISTS FOR USE IN MEDICINE | Biointervene, Inc. (US) | 2023-06-21 | — | — | EP | disclosed |
| WO-2022040241-A1 | A3 ADENOSINE RECEPTOR AGONISTS FOR USE IN MEDICINE | BIOINTERVENE, INC. (US) | 2022-02-24 | — | — | WO | disclosed |